https://orcid.org/0000-0002-1099-7436
References
- ClarkMA, FisherC, JudsonI, et al. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701–711.16107623
- ZagerGK, BalloMT, PestersPW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy; an analysis of 1225 patients. Cancer. 2003;97(10):2530–2543. doi:10.1002/cncr.1136512733153
- WeissSW, GoldblumJR. Local Recurrence In: Enzinger and Weiss’s Soft Tissue Tumors. 4th ed. St. Louis: Mosby; 2001:28–32.
- KaneJM, FinleyJW, DriscollD, et al. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. Sarcoma. 2002;6(2):69–73. doi:10.1080/135771402100002216818521331
- PollockRE, KarnellLH, MenckHR, et al. The national cancer data base report on soft tissue sarcoma. Cancer. 1996;78(10):2247–2257. doi:10.1002/(SICI)1097-0142(19961115)78:10<2247::AID-CNCR29>3.0.CO;2-Y8918421
- JudsonI, VerweijJ, GelderblomH, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled Phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi:10.1016/S1470-2045(14)70063-424618336
- FreezaAM, StacchiottiS, GronchiA. Systematic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):109. doi:10.1186/s12916-017-0872-y28571564
- TapWD, WagnerAJ, SchoffskiP, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323(13):1266–1276. doi:10.1001/jama.2020.170732259228
- DemetriGD, von MehrenM, JonesRL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase iii randomized multicenter clinical trial. J Clin Oncol. 2015;34(8):786–793. doi:10.1200/JCO.2015.62.473426371143
- van der GraafWT, BlayJY, ChawlaSP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi:10.1016/S0140-6736(12)60651-522595799
- SchoffskiP, ChawlaS, MakiRG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicenter, phase 3 trial. Lancet. 2016;387(10028):1629–1637. doi:10.1016/S0140-6736(15)01283-026874885
- NakamuraT, MatsumineA, MatsubaraT, AsanumaK, UchidaA, SudoA. Retrospective analysis of metastatic sarcoma patients. Oncol Lett. 2011;2(2):315–318. doi:10.3892/ol.2011.23822866083
- KaravasilisV, SeddonBM, AshleyS, Al-MuderisO, FisherC, JudsonI. Significant clinical benefit of fist-line palliative chemotherapy in advanced soft-tissue sarcoma. Cancer. 2008;112(7):1585–1591. doi:10.1002/cncr.2333218278813
- SeddonB, StraussSJ, WhelanJ, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–1410. doi:10.1016/S1470-2045(17)30622-828882536
- KawaiA, YonemoriK, TakahashiS, ArakiN, UedaT. Systemic therapy for soft tissue sarcoma: proposal for the optimal use of pazopanib, trabectedin and eribulin. Adv Ther. 2017;34(7):1556–1571. doi:10.1007/s12325-017-0561-428547734